Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
U2-CHOP in Untreated Mantle Cell Lymphoma
NCT04692155Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Aug 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ublituximab, umbralisib in mantle cell lymphoma (MCL), sponsored by University of Alabama at Birmingham. Started Aug 2021; status: terminated.
02
Drugs
ublituximabumbralisib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04692155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04692155.